These include collaborations across the Cancer Research UK funded PREDICT-meso network (https://www.predictmeso.com/our-research-teams/), using biological samples collected within ASSESS-meso to explore genomic, transcriptomic and molecular expression and evolution from pre-malignant states to mesothelioma; diagnostic and response biomarkers such as circulating tumour DNA and serum mesothelin; and the role and importance of the pleural microbiome. This evidence concerns the gene MSLN and mesothelioma.